drug · small molecule
ILLUCCIX
Marketedupdated 3mo agoby $TLX Telix Pharmaceuticals Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 5 investigational indications.
all catalysts(4)
approval · 4
Dec 17, 2021
approval
$TLX
ILLUCCIX (GALLIUM GA-68 GOZETOTIDE) — FDA approval
ILLUCCIX
→
Mar 15, 2023
approval
$TLX
ILLUCCIX (GALLIUM GA-68 GOZETOTIDE) — FDA approval
ILLUCCIX
→
Sep 11, 2025
approval
$TLX
ILLUCCIX (GALLIUM GA-68 GOZETOTIDE) — FDA approval
ILLUCCIX
→
Dec 5, 2025
approval
$TLX
ILLUCCIX (GALLIUM GA-68 GOZETOTIDE) — FDA approval
ILLUCCIX
→
Trials studying ILLUCCIX
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 15, 2028
~2.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Mar 9, 2036method-of-use (U-4002)US 12109277
- Jul 28, 2035method-of-use (U-3317)US 11027031
- Jul 28, 2035method-of-use (U-3317)US 11027031
- Aug 15, 2028compositionUS 113695902.0y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that